A
lexandria Real Estate Equities, Inc. (NYSE: ARE) marks its 32nd anniversary, celebrating its evolution from a garage startup into the pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in the nation’s top life‑science clusters. The company has defined a new commercial asset class—life‑science real estate—critical to U.S. health, economic resilience, and national security, and has accelerated progress on more than 90 % of diseases that still lack effective treatments.
“Life science is at a pivotal moment, facing shifting funding priorities, FDA challenges, capital market volatility, drug‑price pressures, and global competition,” said Joel S. Marcus, Executive Chairman and Founder. “Yet these forces underscore the need for sustained domestic investment to preserve U.S. leadership. In 2025, 44 FDA‑approved therapies were developed or commercialized by Alexandria tenants—39 % of the total—highlighting our role in driving breakthrough medicines.” Marcus added that Alexandria’s Megacampus platform remains essential for scientific advancement and drug development.
Despite a tough market, Alexandria’s asset base—anchored by its differentiated Megacampus ecosystems—continues to dominate demand. Key metrics (as of 30 Sep 2025) include:
- Greater Boston, San Francisco Bay, and San Diego together account for 71 % of annual rental revenue, with a 91 % occupancy rate—18 % above market averages.
- From 1 Jan 2023 to 30 Sep 2025, leasing volume in these three markets exceeded the combined square footage leased by the next five largest life‑science REITs by 105 %.
- Tenant retention averaged over 80 % in the past five years.
These figures underscore the strategic value of Alexandria’s Megacampus model, which delivers scale, flexibility, and a trusted brand that fuels long‑term tenant relationships and operational excellence.
In 2026, Alexandria will advance a public‑private partnership with the Foundation for the National Institutes of Health to leverage precision medicine for depression. The Multi‑Level Assessment & Phenotyping in Depression (MAP‑D) program—initiated to address the unmet need for effective treatments—targets 21 million U.S. adults and $380 billion in annual costs. With design complete, Alexandria is leading a landmark clinical study to identify biomarkers for depression, slated to launch in May during Mental Health Awareness Month.
About Alexandria Real Estate Equities, Inc.
Alexandria is an S&P 500® life‑science REIT founded in 1994 that pioneered the niche of collaborative life‑science real‑estate development. It remains the longest‑tenured owner, operator, and developer of Megacampus™ ecosystems in AAA innovation clusters, including Greater Boston, San Francisco Bay, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of 30 Sep 2025, the company’s market capitalization was $27.8 billion, with 39.1 million RSF of operating properties and 4.2 million RSF of Class A/A+ properties under construction, plus a 100 % pre‑leased project slated for 2026. Alexandria’s venture platform supplies strategic capital to transformative life‑science companies, and its business model delivers high occupancy, long leases, and superior returns. Visit www.are.com for more information.
Forward‑Looking Statements
This release contains forward‑looking statements within the meaning of Sections 27A of the Securities Act of 1933 and 21E of the Securities Exchange Act of 1934, as amended. Statements about Alexandria’s impact on novel medicines, therapies, and cures; its collaborations and investments in depression treatment; the MAP‑D program; and its ability to meet industry needs are based on current expectations and may not materialize. Actual results may differ materially from those expressed. For detailed risk factors, see Alexandria’s filings with the SEC, including its most recent Form 10‑K and quarterly reports.
Contact: Paula Schwartz, Managing Director, Rx Communications Group, (917) 633‑7790, [email protected]
Source: Alexandria Real Estate Equities, Inc.
